Global Peptide-Drug Conjugates(PDCs) CDMO Service Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Page: 114

Published Date: 11 Oct 2024

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.

According to our (Global Info Research) latest study, the global Peptide-Drug Conjugates(PDCs) CDMO Service market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Peptide-Drug Conjugates(PDCs) CDMO Service market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Peptide-Drug Conjugates(PDCs) CDMO Service market size and forecasts, in consumption value ($ Million), 2019-2030
Global Peptide-Drug Conjugates(PDCs) CDMO Service market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Peptide-Drug Conjugates(PDCs) CDMO Service market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Peptide-Drug Conjugates(PDCs) CDMO Service market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Peptide-Drug Conjugates(PDCs) CDMO Service
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Peptide-Drug Conjugates(PDCs) CDMO Service market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include WUXIAPP, Medicilon, Creative Peptides, Peptistar, BOCSCI Inc, HUATENG PHARMA, CPC Scientific Inc, Porton, VIVA Biotech, Taichu Group, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation
Peptide-Drug Conjugates(PDCs) CDMO Service market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segmentation
Peptide-Drug Conjugates(PDCs) CDMO Service market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Therapeutic
    Diagnostic

Market segment by Application
    SME Pharmaceutical Company
    Large Pharmaceutical Company

Market segment by players, this report covers
    WUXIAPP
    Medicilon
    Creative Peptides
    Peptistar
    BOCSCI Inc
    HUATENG PHARMA
    CPC Scientific Inc
    Porton
    VIVA Biotech
    Taichu Group
    PharosGen
    CENTER LABORATORIES, INC
    JIUZHOU Pharmaceutical

Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Peptide-Drug Conjugates(PDCs) CDMO Service product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Peptide-Drug Conjugates(PDCs) CDMO Service, with revenue, gross margin, and global market share of Peptide-Drug Conjugates(PDCs) CDMO Service from 2019 to 2024.
Chapter 3, the Peptide-Drug Conjugates(PDCs) CDMO Service competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Peptide-Drug Conjugates(PDCs) CDMO Service market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Peptide-Drug Conjugates(PDCs) CDMO Service.
Chapter 13, to describe Peptide-Drug Conjugates(PDCs) CDMO Service research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Peptide-Drug Conjugates(PDCs) CDMO Service by Type
        1.3.1 Overview: Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type in 2023
        1.3.3 Therapeutic
        1.3.4 Diagnostic
    1.4 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market by Application
        1.4.1 Overview: Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application: 2019 Versus 2023 Versus 2030
        1.4.2 SME Pharmaceutical Company
        1.4.3 Large Pharmaceutical Company
    1.5 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size & Forecast
    1.6 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast by Region
        1.6.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region: 2019 VS 2023 VS 2030
        1.6.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region, (2019-2030)
        1.6.3 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Prospect (2019-2030)
        1.6.4 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Prospect (2019-2030)
        1.6.5 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Prospect (2019-2030)
        1.6.6 South America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Prospect (2019-2030)
        1.6.7 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Prospect (2019-2030)

2 Company Profiles
    2.1 WUXIAPP
        2.1.1 WUXIAPP Details
        2.1.2 WUXIAPP Major Business
        2.1.3 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.1.4 WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 WUXIAPP Recent Developments and Future Plans
    2.2 Medicilon
        2.2.1 Medicilon Details
        2.2.2 Medicilon Major Business
        2.2.3 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.2.4 Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Medicilon Recent Developments and Future Plans
    2.3 Creative Peptides
        2.3.1 Creative Peptides Details
        2.3.2 Creative Peptides Major Business
        2.3.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.3.4 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Creative Peptides Recent Developments and Future Plans
    2.4 Peptistar
        2.4.1 Peptistar Details
        2.4.2 Peptistar Major Business
        2.4.3 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.4.4 Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Peptistar Recent Developments and Future Plans
    2.5 BOCSCI Inc
        2.5.1 BOCSCI Inc Details
        2.5.2 BOCSCI Inc Major Business
        2.5.3 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.5.4 BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 BOCSCI Inc Recent Developments and Future Plans
    2.6 HUATENG PHARMA
        2.6.1 HUATENG PHARMA Details
        2.6.2 HUATENG PHARMA Major Business
        2.6.3 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.6.4 HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.6.5 HUATENG PHARMA Recent Developments and Future Plans
    2.7 CPC Scientific Inc
        2.7.1 CPC Scientific Inc Details
        2.7.2 CPC Scientific Inc Major Business
        2.7.3 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.7.4 CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.7.5 CPC Scientific Inc Recent Developments and Future Plans
    2.8 Porton
        2.8.1 Porton Details
        2.8.2 Porton Major Business
        2.8.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.8.4 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.8.5 Porton Recent Developments and Future Plans
    2.9 VIVA Biotech
        2.9.1 VIVA Biotech Details
        2.9.2 VIVA Biotech Major Business
        2.9.3 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.9.4 VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.9.5 VIVA Biotech Recent Developments and Future Plans
    2.10 Taichu Group
        2.10.1 Taichu Group Details
        2.10.2 Taichu Group Major Business
        2.10.3 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.10.4 Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.10.5 Taichu Group Recent Developments and Future Plans
    2.11 PharosGen
        2.11.1 PharosGen Details
        2.11.2 PharosGen Major Business
        2.11.3 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.11.4 PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.11.5 PharosGen Recent Developments and Future Plans
    2.12 CENTER LABORATORIES, INC
        2.12.1 CENTER LABORATORIES, INC Details
        2.12.2 CENTER LABORATORIES, INC Major Business
        2.12.3 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.12.4 CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.12.5 CENTER LABORATORIES, INC Recent Developments and Future Plans
    2.13 JIUZHOU Pharmaceutical
        2.13.1 JIUZHOU Pharmaceutical Details
        2.13.2 JIUZHOU Pharmaceutical Major Business
        2.13.3 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
        2.13.4 JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2019-2024)
        2.13.5 JIUZHOU Pharmaceutical Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue and Share by Players (2019-2024)
    3.2 Market Share Analysis (2023)
        3.2.1 Market Share of Peptide-Drug Conjugates(PDCs) CDMO Service by Company Revenue
        3.2.2 Top 3 Peptide-Drug Conjugates(PDCs) CDMO Service Players Market Share in 2023
        3.2.3 Top 6 Peptide-Drug Conjugates(PDCs) CDMO Service Players Market Share in 2023
    3.3 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Overall Company Footprint Analysis
        3.3.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Region Footprint
        3.3.2 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint
        3.3.3 Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value and Market Share by Type (2019-2024)
    4.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Forecast by Type (2025-2030)

5 Market Size Segment by Application
    5.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2024)
    5.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Forecast by Application (2025-2030)

6 North America
    6.1 North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2030)
    6.2 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2019-2030)
    6.3 North America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
        6.3.1 North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2030)
        6.3.2 United States Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        6.3.3 Canada Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        6.3.4 Mexico Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)

7 Europe
    7.1 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2030)
    7.2 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2030)
    7.3 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
        7.3.1 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2030)
        7.3.2 Germany Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        7.3.3 France Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        7.3.4 United Kingdom Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        7.3.5 Russia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        7.3.6 Italy Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)

8 Asia-Pacific
    8.1 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2030)
    8.2 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2030)
    8.3 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region
        8.3.1 Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2019-2030)
        8.3.2 China Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        8.3.3 Japan Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        8.3.4 South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        8.3.5 India Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        8.3.6 Southeast Asia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        8.3.7 Australia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)

9 South America
    9.1 South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2030)
    9.2 South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2030)
    9.3 South America Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
        9.3.1 South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2030)
        9.3.2 Brazil Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        9.3.3 Argentina Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)

10 Middle East & Africa
    10.1 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2030)
    10.2 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2030)
    10.3 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country
        10.3.1 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2030)
        10.3.2 Turkey Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        10.3.3 Saudi Arabia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)
        10.3.4 UAE Peptide-Drug Conjugates(PDCs) CDMO Service Market Size and Forecast (2019-2030)

11 Market Dynamics
    11.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
    11.2 Peptide-Drug Conjugates(PDCs) CDMO Service Market Restraints
    11.3 Peptide-Drug Conjugates(PDCs) CDMO Service Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry

12 Industry Chain Analysis
    12.1 Peptide-Drug Conjugates(PDCs) CDMO Service Industry Chain
    12.2 Peptide-Drug Conjugates(PDCs) CDMO Service Upstream Analysis
    12.3 Peptide-Drug Conjugates(PDCs) CDMO Service Midstream Analysis
    12.4 Peptide-Drug Conjugates(PDCs) CDMO Service Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 4. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2025-2030) & (USD Million)
 Table 5. WUXIAPP Company Information, Head Office, and Major Competitors
 Table 6. WUXIAPP Major Business
 Table 7. WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 8. WUXIAPP Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 9. WUXIAPP Recent Developments and Future Plans
 Table 10. Medicilon Company Information, Head Office, and Major Competitors
 Table 11. Medicilon Major Business
 Table 12. Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 13. Medicilon Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 14. Medicilon Recent Developments and Future Plans
 Table 15. Creative Peptides Company Information, Head Office, and Major Competitors
 Table 16. Creative Peptides Major Business
 Table 17. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 18. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 19. Peptistar Company Information, Head Office, and Major Competitors
 Table 20. Peptistar Major Business
 Table 21. Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 22. Peptistar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 23. Peptistar Recent Developments and Future Plans
 Table 24. BOCSCI Inc Company Information, Head Office, and Major Competitors
 Table 25. BOCSCI Inc Major Business
 Table 26. BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 27. BOCSCI Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 28. BOCSCI Inc Recent Developments and Future Plans
 Table 29. HUATENG PHARMA Company Information, Head Office, and Major Competitors
 Table 30. HUATENG PHARMA Major Business
 Table 31. HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 32. HUATENG PHARMA Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 33. HUATENG PHARMA Recent Developments and Future Plans
 Table 34. CPC Scientific Inc Company Information, Head Office, and Major Competitors
 Table 35. CPC Scientific Inc Major Business
 Table 36. CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 37. CPC Scientific Inc Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 38. CPC Scientific Inc Recent Developments and Future Plans
 Table 39. Porton Company Information, Head Office, and Major Competitors
 Table 40. Porton Major Business
 Table 41. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 42. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 43. Porton Recent Developments and Future Plans
 Table 44. VIVA Biotech Company Information, Head Office, and Major Competitors
 Table 45. VIVA Biotech Major Business
 Table 46. VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 47. VIVA Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 48. VIVA Biotech Recent Developments and Future Plans
 Table 49. Taichu Group Company Information, Head Office, and Major Competitors
 Table 50. Taichu Group Major Business
 Table 51. Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 52. Taichu Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 53. Taichu Group Recent Developments and Future Plans
 Table 54. PharosGen Company Information, Head Office, and Major Competitors
 Table 55. PharosGen Major Business
 Table 56. PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 57. PharosGen Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 58. PharosGen Recent Developments and Future Plans
 Table 59. CENTER LABORATORIES, INC Company Information, Head Office, and Major Competitors
 Table 60. CENTER LABORATORIES, INC Major Business
 Table 61. CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 62. CENTER LABORATORIES, INC Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 63. CENTER LABORATORIES, INC Recent Developments and Future Plans
 Table 64. JIUZHOU Pharmaceutical Company Information, Head Office, and Major Competitors
 Table 65. JIUZHOU Pharmaceutical Major Business
 Table 66. JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product and Solutions
 Table 67. JIUZHOU Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 68. JIUZHOU Pharmaceutical Recent Developments and Future Plans
 Table 69. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (USD Million) by Players (2019-2024)
 Table 70. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Share by Players (2019-2024)
 Table 71. Breakdown of Peptide-Drug Conjugates(PDCs) CDMO Service by Company Type (Tier 1, Tier 2, and Tier 3)
 Table 72. Market Position of Players in Peptide-Drug Conjugates(PDCs) CDMO Service, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 73. Head Office of Key Peptide-Drug Conjugates(PDCs) CDMO Service Players
 Table 74. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Type Footprint
 Table 75. Peptide-Drug Conjugates(PDCs) CDMO Service Market: Company Product Application Footprint
 Table 76. Peptide-Drug Conjugates(PDCs) CDMO Service New Market Entrants and Barriers to Market Entry
 Table 77. Peptide-Drug Conjugates(PDCs) CDMO Service Mergers, Acquisition, Agreements, and Collaborations
 Table 78. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (USD Million) by Type (2019-2024)
 Table 79. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Share by Type (2019-2024)
 Table 80. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Forecast by Type (2025-2030)
 Table 81. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024)
 Table 82. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Forecast by Application (2025-2030)
 Table 83. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 84. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 85. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 86. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 87. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 88. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 89. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 90. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 91. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 92. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 93. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 94. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 95. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 96. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 97. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 98. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 99. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2019-2024) & (USD Million)
 Table 100. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Region (2025-2030) & (USD Million)
 Table 101. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 102. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 103. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 104. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 105. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 106. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 107. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2019-2024) & (USD Million)
 Table 108. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type (2025-2030) & (USD Million)
 Table 109. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2019-2024) & (USD Million)
 Table 110. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application (2025-2030) & (USD Million)
 Table 111. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2019-2024) & (USD Million)
 Table 112. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Country (2025-2030) & (USD Million)
 Table 113. Global Key Players of Peptide-Drug Conjugates(PDCs) CDMO Service Upstream (Raw Materials)
 Table 114. Global Peptide-Drug Conjugates(PDCs) CDMO Service Typical Customers


List of Figures
 Figure 1. Peptide-Drug Conjugates(PDCs) CDMO Service Picture
 Figure 2. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type in 2023
 Figure 4. Therapeutic
 Figure 5. Diagnostic
 Figure 6. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application in 2023
 Figure 8. SME Pharmaceutical Company Picture
 Figure 9. Large Pharmaceutical Company Picture
 Figure 10. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 11. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 12. Global Market Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
 Figure 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 14. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Region in 2023
 Figure 15. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 16. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 17. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 18. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 19. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 20. Company Three Recent Developments and Future Plans
 Figure 21. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Share by Players in 2023
 Figure 22. Peptide-Drug Conjugates(PDCs) CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
 Figure 23. Market Share of Peptide-Drug Conjugates(PDCs) CDMO Service by Player Revenue in 2023
 Figure 24. Top 3 Peptide-Drug Conjugates(PDCs) CDMO Service Players Market Share in 2023
 Figure 25. Top 6 Peptide-Drug Conjugates(PDCs) CDMO Service Players Market Share in 2023
 Figure 26. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Share by Type (2019-2024)
 Figure 27. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Share Forecast by Type (2025-2030)
 Figure 28. Global Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Share by Application (2019-2024)
 Figure 29. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Share Forecast by Application (2025-2030)
 Figure 30. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 31. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 32. North America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 33. United States Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 34. Canada Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 35. Mexico Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 36. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 37. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 38. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 39. Germany Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 40. France Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 41. United Kingdom Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 42. Russia Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 43. Italy Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 44. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 45. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 46. Asia-Pacific Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Region (2019-2030)
 Figure 47. China Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 48. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 49. South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 50. India Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 51. Southeast Asia Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 52. Australia Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 53. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 54. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 55. South America Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 56. Brazil Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 57. Argentina Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 58. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Type (2019-2030)
 Figure 59. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Application (2019-2030)
 Figure 60. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value Market Share by Country (2019-2030)
 Figure 61. Turkey Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 62. Saudi Arabia Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 63. UAE Peptide-Drug Conjugates(PDCs) CDMO Service Consumption Value (2019-2030) & (USD Million)
 Figure 64. Peptide-Drug Conjugates(PDCs) CDMO Service Market Drivers
 Figure 65. Peptide-Drug Conjugates(PDCs) CDMO Service Market Restraints
 Figure 66. Peptide-Drug Conjugates(PDCs) CDMO Service Market Trends
 Figure 67. Porters Five Forces Analysis
 Figure 68. Peptide-Drug Conjugates(PDCs) CDMO Service Industrial Chain
 Figure 69. Methodology
 Figure 70. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

WUXIAPP
Medicilon
Creative Peptides
Peptistar
BOCSCI Inc
HUATENG PHARMA
CPC Scientific Inc
Porton
VIVA Biotech
Taichu Group
PharosGen
CENTER LABORATORIES, INC
JIUZHOU Pharmaceutical

Related Reports

Global Peptide-Drug Conjugates(PDCs) CDMO Service Supply, Demand and Key Producers, 2024-2030

Global Peptide-Drug Conjugates(PDCs) CDMO Service Supply, Demand and Key Producers, 2024-2030

date 11 Oct 2024

date Medical Care

Peptide-drug conjugates (PDCs) consist of a cytotoxic payload, a homing peptide, and a linker between the peptide and the cytotoxic payload. Following antibody-drug conjugates, they are the next generation of targeted therapeutics with enhanced cell permeability and better drug selectivity. They offer excellent opportunities for targeting cancer, metabolic diseases, and more. Although the potential is huge, development challenges such as poor stability, poor targeting, and potential payload toxicity may slow down preclinical and clinical development processes. CDMO services refer to pharmaceutical companies and biotechnology companies outsourcing the research and development and production of their drugs or biologics to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its customization and specialization capabilities, which can meet the specific needs of different customers at different stages.

Product Tags

Peptide-Drug Conjugates(PDCs) CDMO Service

Organ Rejection Prophylaxis Treatment

Biologics Analytical Services

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>